Journal
THORAX
Volume 73, Issue 8, Pages 782-784Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2017-210017
Keywords
-
Categories
Funding
- Spanish Society of Pneumology and Thoracic Surgery (SEPAR)
Ask authors/readers for more resources
Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of followup, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available